Email This Article

Headlines & Perspectives
FDA Panel's Rejection of Xigris Comes as a Painful Shock to Lilly
By Adam Feuerstein
10/16/01 - 06:23 PM EDT
The advisory panel airs concerns over safety and efficacy and votes not to approve the sepsis drug.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,309.92 1,091.49 2,138.44 32.31
Oil *
77.12
DOWN
154.48
DOWN
19.14
DOWN
37.61
DOWN
0.48
10 Yr
3.23%
SPDR Gold
115.06
-1.48%
-1.72%
-1.73%
-1.46%
Data delayed 20 minutes

Brokerage Partners